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Rabbits were imn~unized with a conjugate of leukotriene (LT) C4 and bovine serum albumin prepared by 
coupling the single free amino group of the hapten to the protein using gluteraldehyde. Binding of 
[3H]LTC4 to the antibodies obtained is inhibited by 50% with 1.5 ng LTC4. The relative cross-reaction f 
LTD 4 is 16% and of LTC4-methyl ester 3.6%. The validity of the radioimmunoassay was demonstrated by
comparison with bioassay using the isolated guinea pig ileum. Using the radioimmunoassay it could be 
shown that endogenous LTC4 is released in a dose-dependent manner by human polymorphonuclear 
leucocytes stimulated with the divalent cation ionophore A23187. 




The biological activity of slow-reacting sub- 
stances (SRS) [1,2] is now attributed to a group of 
arachidonic acid metabolites, the leukotrienes 
(LTs) [3,4]. Release of LTs from tissues like human 
lung [5] and various cell populations like neu- 
trophils [6,7], basophils [8,9,10], eosinophils [11] 
and macrophages [12,13] has been described. For 
the quantitative determination of LTs biological, 
chromatographic and physicochemical methods 
have been used [14]. Recently, a radioimmuno- 
assay of the LTs of slow-reacting substance of 
anaphylaxis (SRS-A) has been described [15]. A 
conjugate for immunization of rabbits had been 
prepared by coupling LTD4 via the eicosanoid car- 
boxyl group to bovine serum albumin (BSA). 
However, the antibodies exhibited only limited 
specificity with comparable affinities for LTC4, 
LTD4, LTE4 and their l l-trans stereoisomers. 
More specific antibodies were obtained by immu- 
nization with a conjugate synthesized via the C-5- 
hydroxyl group [16]. Young et al. [17], in a study 
on the preparation of conjugates of LTC4 with 
proteins, have pointed out that coupling pro- 
cedures, which involve reactions on the free 
amino group of the glutamyl residue of LTC4 
should retain the most important parts of the 
hapten molecule unchanged. While these authors 
used either 1,5-difluoro-2,4-dinitrobenzene or 6-N- 
maleimidohexanoic a id chloride as coupling re- 
agents, we here describe the synthesis of an immu- 
nogenic LTCa-BSA conjugate via the single free 
amino group using glutaraldehyde ascoupling re- 
agent [18,19]. The antibodies produced by rabbits 
immunized with this conjugate were used to de- 
velop a radioimmunoassay for LTC4. The sen- 
sitivity and specificity of the assay permit the 
quantitative determination of LTC4 in biological 
material. Thus, while qualitatively the release of 
material identical with SRS-A [20] or LTC4 [7], re- 
spectively, from human polymorphonuclear leuco- 
cytes (PMNs) stimulated by the divalent cation 
ionophore A23187 has been demonstrated, we 
have now used the radioimmunoassay to quantify 
the amounts of LTC4 released under such condi- 
tions. 
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2. MATERIALS AND METHODS 
LTC4 and LTD4 were a generous gift of Dr J. 
Rokach (Merck-Frosst Labs., Pointe-Claire/Dor- 
val, Quebec). Both LTs as well as LTA4-methyl 
ester were also obtained from Ciba (Basle). The 
methyl esters of LTC4 and LTE4 were synthesized 
by Drs Spur, Crea and Falsone (University of 
DUsseldorf). Prostaglandins and thromboxane B2 
were a gift of Dr J. Pike (Upjohn Co., Kalamazoo 
MI). Arachidonic acid (purity -99%) and glu- 
tathione were from Sigma. [14,15-3H]LTC4 (spec. 
act. 28 Ci/mmol) was purchased from New En- 
gland Nuclear Co. 
The LTC4-BSA conjugate used for immuniza- 
tion of rabbits was synthesized using glutaralde- 
hyde as coupling reagent. Briefly, 0.2 mg LTC4 
dissolved in 0.1 ml distilled water was added to a 
solution of 2 mg BSA (Sigma, A grade) in 0.1 ml 
phosphate buffer (0.2 mol/1, pH 7.5). Then 0.1 ml 
0.21 mol/1 glutaraldehyde (Sigma, grade I) was 
added dropwise under continuous tirring. The 
mixture turned yellow within a few minutes and 
was incubated in the dark at room temperature 
overnight. The reaction was stopped by the addi- 
tion of 0.1 ml L-lysine-HC1 (1 mol/l, pH 7.0) and 
the incubate was diluted to 1 ml with 0.1 mol/1 
phosphate buffer (pH 7.5). The conjugate was di- 
alysed against 21 phosphate-buffered saline. The 
preparation was then divided into portions and 
stored at -20°C until used. For immunization 
0.5 mg of the conjugate (in terms of protein) was 
emulsified with an equal volume of complete 
Freund's adjuvant (Difco) and injected into the 
footpads of two rabbits (0.25 mg/animal). Booster 
injections with 0.1 mg immunogen/animal were 
given 1 and 3 weeks later and then at 3-6 weeks 
intervals. The rabbits were bled 10-14 days after 
booster injections. The blood was collected into a 
mixture of sodium EDTA and indomethacin as in 
[21]. Plasma was separated from the blood cells 
immediately by centrifugation at 1500xg at 4°C 
for 15 min. 
For radioimmunoassay an appropriate anti- 
plasma dilution as well as either standard LTC4 or 
unknown samples were added to test tubes con- 
taining [3H]LTC4 (15 000 dpm) in a total volume 
of 0.6 ml. All dilutions were made in Tris-HCl 
buffer (pH 7.4, 0.01 mol/1, containing 0.14 mol/1 
NaCI and 0.1% gelatine). After incubation at 4°C 
overnight antibody-bound and free ligand were 
separated using 0.5 ml charcoal suspension 
(20 mg/ml). After centrifugation the supernatants 
were added to 11 ml Scintigel (Roth, Karlsruhe). 
Their radioactivity was determined in a liquid 
scintillation spectrometer. Bioassay of LTC4 was 
performed as in [22] using the isolated guinea pig 
ileum treated with mepyramine (1 ~tg/ml) and 
atropine (0.2/~g/ml). 
Human PMNs were obtained from heparinized 
blood of healthy donors and separated on a Ficoll 
-metrizoate gradient (Ficoll 400-Pharmacia, Upp- 
sala; sodium metrizoate (75%) Nyegaard and Co., 
Oslo) followed by dextran sedimentation [23]. This 
method leads to > 97% pure PMNs. The cells were 
then washed with TCM buffer and centrifuged at 
low speed (300 x g) 3 times to remove the platelets. 
Human PMNs at various concentrations (1 x 105- 
1 × 107/500/al) were incubated with the ionophore 
A23187. The divalent cation ionophore was ob- 
tained from Serva (Heidelberg). The compound 
(1 mg) was dissolved in ethanol. For cell triggering, 
a dilution of 5 x 10 -6 mol/1 in TCM buffer (pH 
7.35) (mmol/l: Tris, 25; NaC1, 120; KC1, 4.0; 
CaC12, 0.6; MgC12, 1.0) was used. The incubation 
proceeded for 18 min at 37°C and was stopped 
with ice-cold TCM buffer (500 ~1) [24]. The cells 
were then centrifuged at 350xg for 15 min and the 
supernatant was assayed for LTC4 immunoreac- 
tivity. Cells incubated in the absence of ionophore 
served as controls. 
3. RESULTS 
Both rabbits immunized with the LTC4-glu- 
taraldehyde-BSA conjugate produced specific 
antibodies against the hapten. While an anti- 
plasma obtained 12 weeks after first immunization 
binds 20% of the added radioactivity at a final di- 
lution of 1:75, non-specific binding by the same di- 
lution of rabbit plasma obtained before immuniza- 
tion was only 2%. Binding of label to the anti- 
plasma was obviously completely due to "g-globu- 
lins, since the hapten-protein complexes could be 
precipitated by goat anti-rabbit-y-globulin. The 
specificity of the radioimmunoassay for LTC4 is 
shown in table 1. While 50% inhibition of binding 
of label to the antibodies i achieved with 1.5 ng of 
the homologous hapten, the crossreaction of LTD4 
is 16% and of LTC4-methyl ester 3.6%. The other 
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" Table 1 
Specificity of the radioimmunoassay for LTC4 
Ligand Nanograms required Relative cross- 
to displace 50% reaction (%) 
of bound label 
LTC4 1.5 100.0 
LTD4 9.4 16.0 
LTC4-methyl ester 42.0 3.6 
LTA4-methyl ester > 100.0 < 1.5 
LTE4-methyl ester > 100.0 < 1.5 
Glutathione > 100.0 < 1.5 
Arachidonic acid > 100.0 < 1.5 
PGD2 > 100.0 < 1.5 
PGE2 > 100.0 < 1.5 
6-Keto-PGF]~ > 100.0 < 1.5 
TXB2 > 100.0 < 1.5 
compounds tested do not interfere significantly 
with the assay in amounts up to 100 ng. The sen- 
sitivity of the radioimmunoassay permits the de- 
tection of 165 pg LTC4 (10% inhibition of binding 
of label to antiplasma). 
The validity of the radioimmunoassay for LTC4 
was tested by comparison with bioassay (fig.l). For 
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Fig.l. Correlation of data for authentic LTC 4 deter- 
mined either by bioassay or radioimmunoassay. 
<0.01) correlation of results obtained by the two 
methods was observed. 
Using the radioimmunoassay the release of sub- 
stantial amounts of LTC4 from human PMNs 
stimulated with the ionophore A23187 was de- 
tected. There is a clear correlation between the 
amounts of LTC4 found in the incubation medium 
and the number of cells stimulated with the 
ionophore (fig.2). 
4. DISCUSSION 
Although the titer of our anti-LTC4 antiplasma 
is not much higher than that of the antiserum in 
[15], the antibodies produced after immunization 
with the LTC4-glutaraldehyde-BSA conjugate 
are more specific. These antibodies recognize both 
the glutathione and the fatty acid moiety as immu- 
nodominant parts of the LTC4 molecule. This is 
demonstrated bythe fact that LTD4 (lacking the 7- 
glutamyl residue) as well as LTC4 methyl ester 
(lacking the free carboxyl group of the eicosanoid) 
inhibit binding of label to the antibodies much less 
than the homologous hapten LTC4 (table 1). The 
relatively high specificity of the antibodies elicited 
by immunization with the LTC4-glutaraldehyde- 
BSA conjugate as compared to those in [15] may 
be caused by the different coupling procedures 
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Fig.2. Relationship between number of human gran- 
ulocytes incubated with ionophore A23187 (5/~mol/1) 
and release of LTC4 determined by radioimmunoassay. 
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results support the view [17] that coupling the 
hapten via the single free amino group may be ad- 
vantageous leaving the most characteristic parts of 
the hapten unchanged. 
While an excellent correlation of results (fig.l) 
for the determination of authentic LTC4 by radio- 
immunoassay and bioassay was observed, valida- 
tion of radioimmunological data may be more dif- 
ficult, when mixtures of various LTs are present in 
biological material. For determination of LTs in 
such material a chromatographic separation step 
before radioimmunoassay may be necessary [15]. 
On the other hand, the biological activity of SRS 
released from human PMNs incubated with 
ionophore A23187 was found to be mainly com- 
posed of 2 compounds, LTC4 and smaller amounts 
of 1 l-trans-LTC4 [7]. Similarly, synthesis of these 
two LTs as major constituents of SRS was ob- 
served, when LTA4 as exogenous ubstrate had 
been added to human PMNs [25]. In such incu- 
bates containing just one major LT direct deter- 
mination of the immunoreactive compound with- 
out prior separation seems feasible. Although we 
do not yet know the exact interference of 11-trans- 
LTC4 with our assay system, our radioimmunolog- 
ical data are in good agreement with results of JOrg 
et al. [11] obtained by bioassay and ultraviolet 
spectrometry. These authors observed release of 
LTC4 in the same order of magnitude from horse 
neutrophils stimulated by the ionophore A23187 as 
we report here for human PMNs. 
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